Six-Month Follow-Up of Periodontal Condition in Rheumatoid Arthritis and Ankylosing Spondylitis Arthritis Patients Undergoing Anti-Tumour Necrosis Factor-α Therapy
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Evaluation of Oral Status
2.3. Statistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Smolen, J.S.; Landewe, R.B.M.; Bijlsma, J.W.J.; Burmester, G.R.; Dougados, M.; Kerschbaumer, A.; McInnes, I.B.; Sepriano, A.; van Vollenhoven, R.F.; de Wit, M.; et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 2020, 79, 685–699. [Google Scholar] [CrossRef] [PubMed]
- Valesini, G.; Iannuccelli, C.; Marocchi, E.; Pascoli, L.; Scalzi, V.; Di Franco, M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun. Rev. 2007, 7, 35–41. [Google Scholar] [CrossRef] [PubMed]
- Szekanecz, Z.; Szanto, S.; Szabo, Z.; Vancsa, A.; Szamosi, S.; Bodnar, N.; Szucs, G. Biologics—Beyond the joints. Autoimmun. Rev. 2010, 9, 820–824. [Google Scholar] [CrossRef] [PubMed]
- Lundberg, K.; Wegner, N.; Yucel-Lindberg, T.; Venables, P.J. Periodontitis in RA—The citrullinated enolase connection. Nat. Rev. Rheumatol. 2010, 6, 727–730. [Google Scholar] [CrossRef]
- Lappin, D.F.; Apatzidou, D.; Quirke, A.M.; Oliver-Bell, J.; Butcher, J.P.; Kinane, D.F.; Riggio, M.P.; Venables, P.; McInnes, I.B.; Culshaw, S. Influence of periodontal disease, Porphyromonas gingivalis and cigarette smoking on systemic anti-citrullinated peptide antibody titres. J. Clin. Periodontol. 2013, 40, 907–915. [Google Scholar] [CrossRef] [PubMed]
- Martu, M.; Solomon, S.M.; Sufaru, I.G.; Jelihovschi, I.; Martus, S.; Rezus, E.; Surdu, A.E.; Onea, R.M.; Grecu, G.P.; Foia, L. Study on the prevalence of periodontopathogenic bacteria in serum and subgingival bacterial plaque in patients with rheumatoid arthritis. Rev. Chim. 2017, 68, 1946–1949. [Google Scholar] [CrossRef]
- Kang, E.H.; Lee, J.T.; Lee, H.J.; Lee, J.Y.; Chang, S.H.; Cho, H.J.; Choi, B.Y.; Ha, Y.J.; Park, K.U.; Song, Y.W.; et al. Chronic Periodontitis Is Associated with Spinal Dysmobility in Patients with Ankylosing Spondylitis. J. Periodontol. 2015, 86, 1303–1313. [Google Scholar] [CrossRef] [PubMed]
- Keller, J.J.; Kang, J.H.; Lin, H.C. Association between ankylosing spondylitis and chronic periodontitis: A population-based study. Arthritis Rheum. 2013, 65, 167–173. [Google Scholar] [CrossRef]
- Pers, J.O.; Saraux, A.; Pierre, R.; Youinou, P. Anti-TNF-alpha immunotherapy is associated with increased gingival inflammation without clinical attachment loss in subjects with rheumatoid arthritis. J. Periodontol. 2008, 79, 1645–1651. [Google Scholar] [CrossRef]
- Mayer, Y.; Balbir-Gurman, A.; Machtei, E.E. Anti-tumor necrosis factor-alpha therapy and periodontal parameters in patients with rheumatoid arthritis. J. Periodontol. 2009, 80, 1414–1420. [Google Scholar] [CrossRef]
- Mayer, Y.; Elimelech, R.; Balbir-Gurman, A.; Braun-Moscovici, Y.; Machtei, E.E. Periodontal condition of patients with autoimmune diseases and the effect of anti-tumor necrosis factor-alpha therapy. J. Periodontol. 2013, 84, 136–142. [Google Scholar] [CrossRef] [PubMed]
- Kobayashi, T.; Yokoyama, T.; Ito, S.; Kobayashi, D.; Yamagata, A.; Okada, M.; Oofusa, K.; Narita, I.; Murasawa, A.; Nakazono, K.; et al. Periodontal and serum protein profiles in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitor adalimumab. J. Periodontol. 2014, 85, 1480–1488. [Google Scholar] [CrossRef] [PubMed]
- Martu, M.; Rezus, E.; Popa, C.; Solomon, S.M.; Luchian, I.; Pendefunda, A.C.; Sioustis, I.; Anton, D.; Martus, S.; Foia, L. Correlations between systemic therapy with conventional (synthetic) and biological DMARDS, rheumatoid arthritis and periodontal indices of chronic periodontitis. Rom. J. Oral Rehabil. 2018, 10, 161–169. [Google Scholar]
- Zamri, F.; de Vries, T.J. Use of TNF Inhibitors in Rheumatoid Arthritis and Implications for the Periodontal Status: For the Benefit of Both? Front. Immunol. 2020, 11, 591365. [Google Scholar] [CrossRef]
- Ramfjord, S.P.; Knowles, J.W.; Nissle, R.R.; Burgett, F.G.; Shick, R.A. Results following three modalities of periodontal therapy. J. Periodontol. 1975, 46, 522–526. [Google Scholar] [CrossRef] [PubMed]
- Ramfjord, S.P.; Knowles, J.W.; Nissle, R.R.; Shick, R.A.; Burgett, F.G. Longitudinal study of periodontal therapy. J. Periodontol. 1973, 44, 66–77. [Google Scholar] [CrossRef] [PubMed]
- Marton, I.J.; Kiss, C. Overlapping protective and destructive regulatory pathways in apical periodontitis. J. Endod. 2014, 40, 155–163. [Google Scholar] [CrossRef]
- Martos, R.; Tar, I.; Nagy, A.C.; Csosz, E.; Kiss, C.; Marton, I. Hypercitrullination and anti-citrullinated protein antibodies in chronic apical periodontitis, a laboratory investigation. Does autoimmunity contribute to the pathogenesis? Int. Endod. J. 2023, 56, 584–592. [Google Scholar] [CrossRef]
- Lopetuso, L.R.; Gerardi, V.; Papa, V.; Scaldaferri, F.; Rapaccini, G.L.; Gasbarrini, A.; Papa, A. Can We Predict the Efficacy of Anti-TNF-α Agents? Int. J. Mol. Sci. 2017, 18, 1973. [Google Scholar] [CrossRef]
- van Gestel, A.M.; Prevoo, M.L.; van ‘t Hof, M.A.; van Rijswijk, M.H.; van de Putte, L.B.; van Riel, P.L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League against Rheumatism Criteria. Arthritis Rheum. 1996, 39, 34–40. [Google Scholar]
- Anderson, J.J.; Baron, G.; van der Heijde, D.; Felson, D.T.; Dougados, M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001, 44, 1876–1886. [Google Scholar] [CrossRef]
- Silness, J.; Loe, H. Periodontal Disease in Pregnancy. Ii. Correlation between Oral Hygiene and Periodontal Condtion. Acta Odontol. Scand. 1964, 22, 121–135. [Google Scholar] [CrossRef]
- Loe, H.; Silness, J. Periodontal Disease in Pregnancy. I. Prevalence and Severity. Acta Odontol. Scand. 1963, 21, 533–551. [Google Scholar] [CrossRef] [PubMed]
- Bragger, U.; Schurch, E., Jr.; Gusberti, F.A.; Lang, N.P. Periodontal conditions in adolescents with cleft lip, alveolus and palate following treatment in a co-ordinated team approach. J. Clin. Periodontol. 1985, 12, 494–502. [Google Scholar] [CrossRef] [PubMed]
- Anderegg, C.R.; Metzler, D.G. Treatment of the palato-gingival groove with guided tissue regeneration. Report of 10 cases. J. Periodontol. 1993, 64, 72–74. [Google Scholar] [CrossRef]
- Vegh, E.; Kerekes, G.; Pusztai, A.; Hamar, A.; Szamosi, S.; Vancsa, A.; Bodoki, L.; Pogacsas, L.; Balazs, F.; Hodosi, K.; et al. Effects of 1-year anti-TNF-alpha therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis. Rheumatol. Int. 2020, 40, 427–436. [Google Scholar] [CrossRef] [PubMed]
- Gulyas, K.; Horvath, A.; Vegh, E.; Pusztai, A.; Szentpetery, A.; Petho, Z.; Vancsa, A.; Bodnar, N.; Csomor, P.; Hamar, A.; et al. Effects of 1-year anti-TNF-alpha therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. Clin. Rheumatol. 2020, 39, 167–175. [Google Scholar] [CrossRef]
- Tonetti, M.S.; Greenwell, H.; Kornman, K.S. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J. Periodontol. 2018, 89 (Suppl. S1), S159–S172. [Google Scholar]
- Cotti, E.; Abramovitch, K.; Jensen, J.; Schirru, E.; Rice, D.D.; Oyoyo, U.; Torabinejad, M. The Influence of Adalimumab on the Healing of Apical Periodontitis in Ferrets. J. Endod. 2017, 43, 1841–1846. [Google Scholar] [CrossRef]
- Knowles, J.W.; Burgett, F.G.; Nissle, R.R.; Shick, R.A.; Morrison, E.C.; Ramfjord, S.P. Results of periodontal treatment related to pocket depth and attachment level. Eight years. J. Periodontol. 1979, 50, 225–233. [Google Scholar] [CrossRef]
- Werner, N.; Heck, K.; Walter, E.; Ern, C.; Bumm, C.V.; Folwaczny, M. Probing pocket depth reduction after non-surgical periodontal therapy: Tooth-related factors. J. Periodontol. 2023, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Loe, H.; Theilade, E.; Jensen, S.B. Experimental Gingivitis in Man. J. Periodontol. (1930) 1965, 36, 177–187. [Google Scholar] [CrossRef] [PubMed]
- Hajishengallis, G.; Korostoff, J.M. Revisiting the Page & Schroeder model: The good, the bad and the unknowns in the periodontal host response 40 years later. Periodontol. 2000 2017, 75, 116–151. [Google Scholar]
- Figueredo, C.M.; Lira-Junior, R.; Love, R.M. T and B Cells in Periodontal Disease: New Functions in a Complex Scenario. Int. J. Mol. Sci. 2019, 20, 3949. [Google Scholar] [CrossRef] [PubMed]
- Demoersman, J.; Pochard, P.; Framery, C.; Simon, Q.; Boisrame, S.; Soueidan, A.; Pers, J.O. B cell subset distribution is altered in patients with severe periodontitis. PLoS ONE 2018, 13, e0192986. [Google Scholar] [CrossRef] [PubMed]
- Weissmann, G. The pathogenesis of rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis. 2006, 64, 12–15. [Google Scholar] [CrossRef]
- Brown, M.A. Genetics and the pathogenesis of ankylosing spondylitis. Curr. Opin. Rheumatol. 2009, 21, 318–323. [Google Scholar] [CrossRef]
- Watad, A.; Amital, H. ACPAs Are much More Than Diagnostic Autoantibodies. Rambam Maimonides Med. J. 2016, 7, e0028. [Google Scholar] [CrossRef]
- Lu, M.C.; Lai, N.S.; Yin, W.Y.; Yu, H.C.; Huang, H.B.; Tung, C.H.; Huang, K.Y.; Yu, C.L. Anti-citrullinated protein antibodies activated ERK1/2 and JNK mitogen-activated protein kinases via binding to surface-expressed citrullinated GRP78 on mononuclear cells. J. Clin. Immunol. 2013, 33, 558–566. [Google Scholar] [CrossRef]
- Meyer, P.W.; Hodkinson, B.; Ally, M.; Musenge, E.; Wadee, A.A.; Fickl, H.; Tikly, M.; Anderson, R. Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis. Mediat. Inflamm. 2010, 2010, 158514. [Google Scholar] [CrossRef]
- Navarro-Millan, I.; Sattui, S.E.; Curtis, J.R. Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis. Clin. Ther. 2013, 35, 1850–1861.e1. [Google Scholar] [CrossRef] [PubMed]
RA | AS | Total | |
---|---|---|---|
n | 13 | 11 | 24 |
female:male | 10:3 | 3:8 | 13:11 |
age (mean ± SD) (range), years | 55.9 ± 9.8 (35–74) | 43.6 ± 12.4 (21–62) | 48.8 ± 13.8 (21–74) |
disease duration (mean ± SD) (range), years | 9.1 ± 8.3 (1-–33) | 7.2 ± 7.0 (1–26) | 8.3 ± 6.2 (1–33) |
RF positivity, n (%) | 10 (77) | - | - |
ACPA positivity, n (%) | 11 (85) | - | - |
DAS28 (baseline) (mean ± SD) | 4.88 ± 0.79 | - | - |
BASDAI (baseline) (mean ± SD) | - | 5.56 ± 1.22 | - |
Treatment (ETN, CZP) | 9 ETN, 4 CZP | 11 ETN | 20 ETN, 4 CZP |
Mean ± SD | Significance | |
---|---|---|
PI-0 * | 0.61 ± 0.61 | n.s. |
PI-6 * | 0.52 ± 0.63 | |
GI-0 | 0.65 ± 0.34 | p < 0.05 |
GI-6 | 0.88 ± 0.30 | |
BOP-0 | 0.06 ± 0.23 | n.s. |
BOP-6 | 0.19 ± 0.13 | |
CPD-0 | 1.60 ± 0.74 | n.s. |
CPD-6 | 1.49 ± 0.48 | |
CPDmax-0 | 4.00 ± 1.94 | p < 0.05 |
CPDmax-6 | 2.72 ± 1.36 | |
CAL-0 | 2.14 ± 1.98 | n.s. |
CAL-6 | 2.10 ± 1.28 | |
CALmax-0 | 5.22 ± 2.56 | p < 0.05 |
CALmax-6 | 2.72 ± 1.36 |
Mean ± SD | Significance | |
---|---|---|
age-R (years) | 52.7 ± 11.8 | p < 0.05 |
age-NR (years) | 37.2 ± 13.4 | |
PI1-R | 0.61 ± 0.68 | n.s. |
PI1-NR | 0.29 ± 0.15 | |
GI1-R | 0.65 ± 0.39 | p < 0.05 |
GI1-NR | 0.52 ± 0.07 | |
BOP1-R | 0.06 ± 0.23 | n.s. |
BOP1-NR | 0.00 ± 0.00 | |
CPD1-R | 1.60 ± 0.74 | n.s. |
CPD1-NR | 1.28 ± 0.39 | |
CPD1max-R | 4.00 ± 1.94 | n.s. |
CPD1max-NR | 2.83 ± 1.83 | |
CAL1-R | 2.14 ± 2.14 | n.s. |
CAL1-NR | 1.37 ± 1.37 | |
CAL1max-R | 5.22 ± 2.46 | n.s. |
CAL1max-NR | 3.17 ± 2.40 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tar, I.; Végh, E.; Martos, R.; Soós, B.; Márton, I.; Szekanecz, Z. Six-Month Follow-Up of Periodontal Condition in Rheumatoid Arthritis and Ankylosing Spondylitis Arthritis Patients Undergoing Anti-Tumour Necrosis Factor-α Therapy. J. Clin. Med. 2024, 13, 448. https://doi.org/10.3390/jcm13020448
Tar I, Végh E, Martos R, Soós B, Márton I, Szekanecz Z. Six-Month Follow-Up of Periodontal Condition in Rheumatoid Arthritis and Ankylosing Spondylitis Arthritis Patients Undergoing Anti-Tumour Necrosis Factor-α Therapy. Journal of Clinical Medicine. 2024; 13(2):448. https://doi.org/10.3390/jcm13020448
Chicago/Turabian StyleTar, Ildikó, Edit Végh, Renáta Martos, Boglárka Soós, Ildikó Márton, and Zoltán Szekanecz. 2024. "Six-Month Follow-Up of Periodontal Condition in Rheumatoid Arthritis and Ankylosing Spondylitis Arthritis Patients Undergoing Anti-Tumour Necrosis Factor-α Therapy" Journal of Clinical Medicine 13, no. 2: 448. https://doi.org/10.3390/jcm13020448
APA StyleTar, I., Végh, E., Martos, R., Soós, B., Márton, I., & Szekanecz, Z. (2024). Six-Month Follow-Up of Periodontal Condition in Rheumatoid Arthritis and Ankylosing Spondylitis Arthritis Patients Undergoing Anti-Tumour Necrosis Factor-α Therapy. Journal of Clinical Medicine, 13(2), 448. https://doi.org/10.3390/jcm13020448